Skip to main content
OpenTrials
Completed

NCT Number: NCT03048435

Cervical Ca PROs in Clinical Practice

Concurrent chemo-radiotherapy followed by intracavitary brachytherapy is standard of care for patients with locally advanced cervical cancer. Although curative, this treatment is challenging and leaves a significant proportion of women with severe toxicity, negatively impacting their quality of life. Although most recover over time, a proportion of women do not. Therefore, evaluation of quality of life becomes increasingly more important as cancer specific outcomes improve. One such method is through patient-reported outcomes (PROs), defined as "any report coming directly from the patient about a health condition and its treatment." This prospective multi-institutional study, involving the Princess Margaret (PM), Odette Regional Cancer Centre(ORCC) and Royal Victoria Regional Health Center (RVH), will assess to feasibility and acceptability of integrating a cervical cancer specific PRO measurement tool into clinical practice. Cervical cancer patients coming for follow-up appointments will be asked to complete the EORTC QLQ-CX24, a validated cervical cancer specific PRO questionnaire. At the end of the study period, Feedback Forms will be completed by participating patients and health care providers to obtain their perspectives regarding the feasibility and acceptability of incorporating the instrument into clinical practice. Future directions include designing an electronic platform and expanding its use in cervical cancer clinics provincially and nationally. The data collected should help identify disease-related symptoms, treatment-related toxicities, facilitate patient-physician communication, shared treatment planning and target intervention strategies.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Royal Victoria Regional Health Centre, Barrie, Ontario, Canada

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Patient Inclusion Criteria:

  • Adult (> 18 years) English speaking patients
  • Treated with curative intent with chemo-radiotherapy
  • Seen in routine clinic follow-up within 5 years post completion of treatment

Patient Exclusion Criteria:

  • Patients at their anticipated last clinic visit prior to cancer center discharge
  • Patients unable to complete the EORTC QLQ CX-24 questionnaire due to inability to read or write.
  • Non-English speaking patients
  • Patients of the principal investigator. The rationale for this is that patients of the principal investigator who complete the Feedback form may be biased and this may be reflected in the results.

Oncologist Inclusion Criteria:

  • Oncologists who treat cervix cancer
  • Oncologists with at least one consenting patient enrolled in the study

Oncologist Exclusion Criteria:

  • Principal investigator listed on the protocol. The rationale for this is that oncologists who are also investigators on this study may have inherent bias in the study which may be reflected in the results of the Feedback form.

Treatment and study plan

EORTC QLQ CX-24

Other

Disease specific Patient Reported Outcome measurement tool developed by the European Organization for Research and Treatment of Cancer (EORTC). This questionnaire covers symptoms common to women with cervical cancer and captures the impact of disease and/or treatment on domains including: urologic and gastro-intestinal symptoms, sexual functioning and body image.

Other names: Quality of Life questionnaire

Physician Feedback Form

Other

This Feedback form to be completed by oncologists who have had at least one consenting patient participating in this study.

Primary outcomes

  1. Percentage of EORTC QLQ CX24 questionnaire completed

    Time frame: 9 months

    Gather information on feasibility of administering questionnaire

  2. Percentage of favorable scores (Agree or strongly agree) on Feedback Form

    Time frame: 9 months

    Gather information on acceptability of incorporating the questionnaire in routine follow-up

Sponsors and collaborators

Lead sponsor

University Health Network, Toronto

Other

Registry information

Official study title

Feasibility and Acceptability of Measuring Cervical Cancer Specific Patient-Reported Outcomes in Clinical Practice

Important dates

Study start
2017
Primary completion
2020
Study completion
2020
First posted
Feb 9, 2017
Registry last updated
Oct 5, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.